PHARM Y1 S2: Anti-Inflammatory Agents Flashcards

1
Q

inflammatory mediators which induce and potentiate pain

A
  • induce: histamine, bradykinin, 5-HT (serotonin)
  • potentiate (amplify): eicosanoids (e.g. prostaglandins)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

prostacyclin (PGI2)
- where is it made
- what are its functions

A
  • made in endothelium
  • function: vasodilation, hyperalgesic, decreased platelet aggregation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

location and function of PGD2

A
  • mast cells
  • vasodilation
  • decreased platelet aggregation
  • GIT relaxation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

location and function of PGE2

A
  • GIT
  • vasodilator
  • decreased gastric acid secretion
  • fever
  • hyperalgesia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

location and functions of PGF2a

A
  • myometrium and lungs
  • bronchoconstrictor
  • myometrial contraction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

thromboxane (Txa2) location and function

A
  • generated in platelets
  • promotes thrombosis
  • vasoconstriction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what do NSAIDs target?

A
  • inhibit cyclo-oxygenases which convert arachidonic acid into prostaglandins
  • decreased prostaglandins = decreased inflammation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

function of COX-1 and what eicosanoids does it generate?

A
  • “constitutive”, involved in housekeeping and homeostasis
  • generates PGD2, PGE2, PGI2, thromboxane (TxA2), PGF2a,
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

function of COX-2 and what eicosanoids does it generate?

A
  • induced in inflammatory cells when activated = “inducible”
  • generates PGD2, PGE2, PGI2 (NOT TxA2 or PGF2a - these are COX-1)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

side effects of non-selective COX inhibitors (i.e. target both COX-1 and COX-2)

A
  • increased bleeding time b/c decreased TxA2 (COX-1) = decreased clotting
  • peptic ulcers b/c decreased PGE2 (COX-1 and 2) = increased gastric acid secretion = GIT irritation
  • exacerbation of asthma b/c arachidonic acid is instead converted into leukotrienes by lipoxygenase > bronchoconstrictors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

how are NSAIDs metabolised?

A
  • by CYP-450 enzymes in liver
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

aspirin: MOA and function

A
  • @ low doses: selective IRREVERSIBLE COX-1 inhibitor > anti-clotting
  • @ higher doses: non-selective COX inhibitor > anti-inflammatory, analgesic, antipyretic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

why is aspirin more readily absorbed in the stomach?

A
  • aspirin is a weak acid
  • therefore in acidic environments it becomes unionised and therefore more lipid soluble
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

how does aspirin overdose work?
- Sx and Tx

A
  • too much aspirin = saturate the enzymes that break it down into salicylic acid
  • Sx: tinnitus, deafness, confusion, convulsions, coma, death
  • Tx: CVS and resp support, then correct acid-base balance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

how to correct acid-base balance re: aspirin overdose

A
  • activated charcoal: porous and binds to aspirin > prevent further absorption and promote excretion
  • rid body of salicylic acid: forced alkaline diuresis using IV bicarbonate or haemodialysis (severe)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

ibuprofen AND diclofenac (voltaren)
- MOA
- functions
- side effects

A
  • inhibits both COX-1 and COX-2
  • anti-inflammatory, analgesic, antipyretic
  • increased bleeding, peptic ulcers, renal effects
17
Q

celecoxib AND meloxicam
- MOA
- functions
- risks

A
  • selective COX-2 inhibitor
  • decreases inflammation w/ LESS GI effects
  • analgesic, anti-inflammatory, antipyretic
  • increase risk of AMI due to inhibition of PGI2 (anti-clot), allowing TxA2 (pro-clot) to dominate
  • more sodium retained since PGE2 is inhibited = increased BP = risk of AMI
18
Q

paracetamol
- MOA
- function

A
  • simple analgesic + antipyretic, unknown MOA
  • no anti-inflammatory effect and avoids GI side effects b/c not impacting COX-1 and 2
  • useful when aspirin is contraindicated e.g. peptic ulcer, coagulation disorder
19
Q

paracetamol overdose
- what happens?
- why might this occur?

A
  • lots of paracetamol = saturate enzymes which make it water soluble in liver = instead converted to toxic metabolite NAPQI = liver damage
  • can occur due to deliberate poisoning, accidental paediatric exposure, inadvertent repeated subtherapeutic ingestions
20
Q

treatment for paracetamol overdose

A
  • N-acetylcysteine
  • inactivates toxic metabolite NAPQI so it can be excreted
21
Q

breakdown of membrane phospholipid > prostaglandin production pathway

22
Q

analgesic ladder

A
  • start w/ simple analgesics (paracetamol)
  • then NSAIDs if inflammation present
  • then weak opioids +/- simple analgesics
  • then strong opioids +/- simple analgesics
23
Q

function of adrenal cortex

A
  • zona glomerulosa (outermost layer): mineralocorticoids
  • zona fasciculata: glucocorticoids
  • zona reticularis: androgens (sex hormones)
  • all have cholesterol as a precursor
24
Q

glucocorticoids function

A
  • slow onset of action
  • regulate CHO and protein metabolism (stress response)
  • anti-inflammatory (can also address loss of function) and immunosuppressive
25
Q

mineralocorticoids function

A
  • regulate water and electrolyte (Na/K) balance
26
Q

Addison’s disease, Sx, Tx

A
  • deficiency in synthesis of endogenous hydrocortisone due to sudden withdrawal of glucocorticoids
  • Sx: weakness, lethargy, dehydration, hypotension
  • Tx: hydrocortisone replacement therapy
27
Q

MOA of glucocorticoids

A
  • enter cell and bind to glucocorticoid receptor in cytosol
  • moves to nucleus (NUCLEAR RECEPTORS) and decreases transcription of inflammatory cytokines OR increases anti-inflammatory proteins e.g. lipocortin-1
  • this inhibits phospholipase A2 which converts membrane phospholipids into arachidonic acid (prevents synthesis of leukotrienes = prevent bronchoconstriction)
28
Q

endogenous vs synthetic glucocorticoids

A
  • endogenous glucocorticoids possess mineralocorticoid activity which can lead to side effects
  • exogenous: no mineralocorticoid activity
29
Q

drug interactions w/ glucocorticoids

A
  • increase activity of CYP3A4 enzyme in liver > increased metabolism of other drugs
  • more likely to have interactions if administered IV/IM compared to topical
30
Q

why are glucocorticoids useful in life threatening situations?

A
  • can give a massive ‘one-off’ dose (harmless) b/c side effects like immunosuppression come from prolonged use
  • h/w sudden withdrawal can result in adrenal insufficiency (takes time to start producing endogenous glucocorticoids again) > Addison’s disease
31
Q

what conditions can we use glucocorticoids for?

A
  • eye inflammation
  • rheumatoid arthritis
  • allergies e.g. hayfever, dermatitis, bee stings, asthma
32
Q

2 stages of asthma and which stage do glucocorticoids target?

A
  • immediate: bronchospasm
  • late: inflammatory reaction + mucus plug
  • glucocorticoids prevent late phase, NOT bronchospasm
33
Q

best way to administer glucocorticoids for asthma

A
  • inhaled: goes straight to site of action
  • B agonists increase penetration and cause bronchodilation
  • can also give oral in short term but leads to systemic side effects
34
Q

side effects of glucocorticoids

A
  • increased susceptibility to hyperglycaemia
  • growth suppression and muscle wasting in kids
  • osteoporosis (decreased Ca2+ absorption and increased renal excretion)
  • HTN
  • increased risk of infection (hidden symptoms)
35
Q

Cushing’s syndrome

A
  • opposite to Addison’s syndrome, due to long-term corticosteroid exposure
  • Sx: easy bruising (purpura), increased abdominal fat, poor wound healing, thinning of skin, HTN, diabetes, thin bones, moon-shaped face
36
Q

examples of glucocorticoids

A
  • prednisolone
  • dexamethasone: eye inflammation, fever
  • fluticasone: prevents asthma
37
Q

what do the new generation NSAIDs primarily target

A
  • COX-2 only